A searchable database of
medically documented cases

About the Project

Delayed Spontaneous Remission In A Child With Primary Acquired Chronic Pure Red Cell Aplasia

Khalil et al., 2010Other/Unknown

Khalil, A., Elhasid, R., Ben Barak, A., & Ben Arush, M. W. (2010). Delayed spontaneous remission in a child with primary acquired chronic pure red cell aplasia. Pediatric hematology and oncology, 27(7), 574–580. https://doi.org/10.3109/08880018.2010.493577

View Original Source →

Abstract

The acquired form of pure red cell aplasia (PRCA) presents either as an acute self-limited disease, predominantly seen in children, or as a chronic illness more frequently seen in adults with rare spontaneous remissions. A 14-year-old boy presented with pallor, without hepatosplenomegaly, jaundice, lymphadenopathy, petechiae, or any other apparent abnormalities. Isolated anemia in the presence of normal white cell and platelet counts with a marrow of normal cellularity and absence of erythroblasts but normal myeloid cells and megakaryocytes revealed the diagnosis of PRCA. All possible investigations excluded secondary causes of PRCA. The patient required packed red cell transfusions every 2 to 3 weeks. He failed therapy with intravenous immunoglobulin, corticosteroids, cyclosporine A plus corticosteroids, antithymocyte globulin, anti-CD 20 (rituximab), and erythropoietin (EPO). He showed a severe, resistant, and transfusion-dependent PRCA. Spontaneous remission with normal hemoglobin and reticulocyte levels was dramatic 6.5 years after the diagnosis of PRCA and 3.6 years after his last treatment.

Case Details

Disease Location

Blood

Personal Characteristics

14 years old israeli arab boy

Clinical Characteristics

History of pallor. Symptoms of upper respiratory tract infection. Diagnosis of aquire pure red cell aplasia.

Remission Characteristics

Dramatic spontaneous remission 6.5 years from the diagnosis of prca

Treatment & Mechanisms

Proposed Remission Mechanisms

Some unknown factor may have been contained in the transfused packed red cells and inhibited or adsorbed autoantibodies or inhibited its production

Clinical Treatment

Blood transfusion. Treatment with intravenous immunoglobulin. Cyclosporin a. Prednisone. Antithymocyte globulin.anti-CD20 monoclonal antibody (rituximab).horse atg. High-dose methylprednisolone. Iron chelation.